期刊文献+

替吉奥胶囊临床研究进展 被引量:32

Compound Tegafur Capsules for Clinical Research Progress
暂未订购
导出
摘要 替吉奥胶囊是替加氟及优福定的升级换代产品,其疗效明显优于替加氟、优福定和5-氟尿嘧啶,目前已作为用于治疗胃癌、头颈部癌和多种晚期转移癌等的一线治疗药物。本品毒副作用小,疗效确切,给药方便,可取得良好的效益。 Compound tegafur capsule is the upgrading of product for tegafur and UFT,its efficacy is better than tegafur,good for UFT and 5-FU. Now It has been used to treat cancer,head and neck cancer and a variety of advanced metastatic cancer,such as the first-line treatment drug. It has small drug side effects, the curative effect is accurate. It will be made good benefits.
机构地区 扬子江药业集团
出处 《中国现代医生》 2008年第30期62-63,共2页 China Modern Doctor
关键词 替吉奥胶囊 胃癌 效益 Compound tegafur capsule Gastric cancer Benefits
  • 相关文献

参考文献3

二级参考文献18

  • 1余更生,林大任,李明毅,邓旭霞.长春瑞滨联合亚叶酸、氟尿嘧啶治疗铂类耐药的复发或转移的鼻咽癌[J].中国癌症杂志,2004,14(4):376-377. 被引量:5
  • 2Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5 - fluorouracil (capecitabine, UFT, S-1): A review. Oncologist, 2002; 7 (4): 288 -323
  • 3Hoff PM. the tegafur - based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin and S- 1: A review of their clinical development and therapeutic potential, Invest New Drugs, 2000; 18 (4) : 331 - 342
  • 4白坂哲彦 佃守 犬山征夫他.新规经口抗癌剂TS-1(S-1)[J].癌と化学疗法(日文),2001,28(6):855-864.
  • 5Hirata K, Horikoshi N, Aiba K, et at. Pharmacokinetic study of S - 1, a novel oval fluorouracil antitumor drug. Clin Cancer Res, 1999; 5 (8) : 2000- 2005
  • 6Aventis - Sanofi Group. S - 1 oral antlcancer agent improves patients' survival in adjuvant gastric cancer trial versus surgery alone (Press releases)o http:// en. sanofi-aventis.com/press/ppc-15653.asp (January 19, 2007)
  • 7Maehara Y. S - 1 in gastric cancer: A comprehensive review. Gastric Cancer, 2003; 6 (Suppl 1) : 2- 8
  • 8Nagashima F, Ohtsu A, Yoshida S, et al. Japanese nationwide post - marketing survey of S - 1 in patients with advanced gastric cancer. Gastric Cancer, 2005; 8 (1): 6-11
  • 9Aventis - Sanofi Group. S - 1, a novel oral fluoropyrimidine, when combined with cisplatin, demonstrates significant improvement in overall survival of advanced gastric cancer patients over S - 1 alone (Press releases) . http:// en. sanofi - aventis.com/press/ppc-16728.asp (June 3, 2007)
  • 10Ohtsu A, Baba H, Sakata Y, et al. Phase Ⅱ study of S - 1, a novel oral fluoro- phyrimidine derivative, in patients with metastatic cotorectal carcinoma. Br J Cancer, 2(XX); 83 (2) : 141-145

共引文献66

同被引文献244

引证文献32

二级引证文献186

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部